284 related articles for article (PubMed ID: 25030803)
21. Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial.
Kashani L; Shams N; Moazen-Zadeh E; Karkhaneh-Yousefi MA; Sadighi G; Khodaie-Ardakani MR; Rezaei F; Rahiminejad F; Akhondzadeh S
J Psychiatr Res; 2017 Nov; 94():70-77. PubMed ID: 28688338
[TBL] [Abstract][Full Text] [Related]
22. Effect of Pregnenolone vs Placebo on Self-reported Chronic Low Back Pain Among US Military Veterans: A Randomized Clinical Trial.
Naylor JC; Kilts JD; Shampine LJ; Parke GJ; Wagner HR; Szabo ST; Smith KD; Allen TB; Telford-Marx EG; Dunn CE; Cuffe BT; O'Loughlin SH; Marx CE
JAMA Netw Open; 2020 Mar; 3(3):e200287. PubMed ID: 32119096
[TBL] [Abstract][Full Text] [Related]
23. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
Goff DC; Cather C; Gottlieb JD; Evins AE; Walsh J; Raeke L; Otto MW; Schoenfeld D; Green MF
Schizophr Res; 2008 Dec; 106(2-3):320-7. PubMed ID: 18799288
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
Haig GM; Wang D; Zhao J; Othman AA; Bain EE
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 28922590
[TBL] [Abstract][Full Text] [Related]
25. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Brown D; Nakagome K; Cordes J; Brenner R; Gründer G; Keefe RSE; Riesenberg R; Walling DP; Daniels K; Wang L; McGinniss J; Sand M
Schizophr Bull; 2019 Mar; 45(2):350-359. PubMed ID: 29718385
[TBL] [Abstract][Full Text] [Related]
27. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
28. Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction.
Rajagopal L; Soni D; Meltzer HY
Behav Brain Res; 2018 Sep; 350():31-43. PubMed ID: 29763637
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
Findling RL; McKenna K; Earley WR; Stankowski J; Pathak S
J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):327-42. PubMed ID: 23083020
[TBL] [Abstract][Full Text] [Related]
30. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
31. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
32. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
33. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
34. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
[TBL] [Abstract][Full Text] [Related]
35. Does Pregnenolone Adjunct to Risperidone Ameliorate Irritable Behavior in Adolescents With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial?
Ayatollahi A; Bagheri S; Ashraf-Ganjouei A; Moradi K; Mohammadi MR; Akhondzadeh S
Clin Neuropharmacol; 2020; 43(5):139-145. PubMed ID: 32947424
[TBL] [Abstract][Full Text] [Related]
36. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
37. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
Schoemaker JH; Jansen WT; Schipper J; Szegedi A
J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
[TBL] [Abstract][Full Text] [Related]
38. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
[TBL] [Abstract][Full Text] [Related]
39. Calibration and cross-validation of MCCB and CogState in schizophrenia.
Lees J; Applegate E; Emsley R; Lewis S; Michalopoulou P; Collier T; Lopez-Lopez C; Kapur S; Pandina GJ; Drake RJ
Psychopharmacology (Berl); 2015 Nov; 232(21-22):3873-82. PubMed ID: 26018529
[TBL] [Abstract][Full Text] [Related]
40. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
Barnes TR; Leeson VC; Paton C; Costelloe C; Simon J; Kiss N; Osborn D; Killaspy H; Craig TK; Lewis S; Keown P; Ismail S; Crawford M; Baldwin D; Lewis G; Geddes J; Kumar M; Pathak R; Taylor S
Health Technol Assess; 2016 Apr; 20(29):1-46. PubMed ID: 27094189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
